Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Inv. presentation Acq. announced CC transcript
|
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
08/08/2023 |
8-K
| Quarterly results |
07/17/2023 |
8-K
| Quarterly results |
06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
05/09/2023 |
8-K
| Quarterly results |
02/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Tranche 2 Warrant Agreement, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates",
"Loan and Security Agreement, as amended by the First Amendment to Loan and Security Agreement, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc" |
|
01/10/2023 |
8-K
| Other Events Interactive Data |
12/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Legal Opinion of Hogan Lovells US LLP",
"Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto",
"Amendment No. 2, to Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the signature pages thereto",
"Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program" |
|
12/19/2022 |
8-K
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
08/04/2022 |
8-K
| Quarterly results |
06/17/2022 |
8-K
| Quarterly results |
05/09/2022 |
8-K
| Quarterly results |
05/09/2022 |
8-K
| Quarterly results |
02/24/2022 |
8-K
| Quarterly results |
11/04/2021 |
8-K
| Quarterly results |
08/05/2021 |
8-K
| Quarterly results |
06/21/2021 |
8-K
| Quarterly results |
06/01/2021 |
8-K
| Quarterly results |
05/18/2021 |
8-K
| Quarterly results |
05/06/2021 |
8-K
| Quarterly results |
02/25/2021 |
8-K
| Quarterly results |
11/05/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
11/05/2020 |
8-K
| Quarterly results |
08/06/2020 |
8-K
| Quarterly results |
06/18/2020 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/07/2020 |
8-K
| Quarterly results |
02/26/2020 |
8-K
| Quarterly results |
12/12/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
12/10/2019 |
8-K
| Quarterly results |
11/06/2019 |
8-K
| Quarterly results |
08/07/2019 |
8-K
| Quarterly results |
|
|
|